Sen. John Boozman Sells Off Shares of AbbVie Inc. (NYSE:ABBV)

Senator John Boozman (R-Arkansas) recently sold shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on September 12th, the Senator disclosed that they had sold between $1,001 and $15,000 in AbbVie stock on August 22nd.

Senator John Boozman also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 8/22/2025.
• Sold $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 8/22/2025.
• Purchased $1,001 – $15,000 in shares of Eli Lilly and Company (NYSE:LLY) on 8/22/2025.
• Purchased $1,001 – $15,000 in shares of Eli Lilly and Company (NYSE:LLY) on 8/11/2025.
• Sold $1,001 – $15,000 in shares of AbbVie (NYSE:ABBV) on 8/11/2025.
• Purchased $1,001 – $15,000 in shares of Advanced Micro Devices (NASDAQ:AMD) on 8/7/2025.
• Purchased $1,001 – $15,000 in shares of iShares MBS ETF (NASDAQ:MBB) on 8/1/2025.
• Sold $1,001 – $15,000 in shares of iShares MSCI EAFE ETF (NYSEARCA:EFA) on 8/1/2025.
• Purchased $1,001 – $15,000 in shares of Goldman Sachs ActiveBeta Emerging Markets Equity ETF (NYSEARCA:GEM) on 8/1/2025.
• Purchased $1,001 – $15,000 in shares of iShares 7-10 Year Treasury Bond ETF (NASDAQ:IEF) on 8/1/2025.

AbbVie Stock Performance

Shares of ABBV stock opened at $220.16 on Thursday. The firm has a market capitalization of $388.93 billion, a price-to-earnings ratio of 104.84, a price-to-earnings-growth ratio of 1.39 and a beta of 0.53. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61. The business has a fifty day moving average of $201.98 and a 200 day moving average of $194.84. AbbVie Inc. has a 1 year low of $163.81 and a 1 year high of $221.76.

AbbVie (NYSE:ABBV) last issued its earnings results on Thursday, July 31st. The company reported $2.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.24 by ($0.27). The firm had revenue of $15.42 billion during the quarter, compared to analysts’ expectations of $14.93 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The business’s revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the business earned $2.65 EPS. As a group, research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 14th. Investors of record on Wednesday, October 15th will be paid a $1.64 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $6.56 dividend on an annualized basis and a yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is 312.38%.

Institutional Investors Weigh In On AbbVie

Institutional investors have recently bought and sold shares of the company. Brighton Jones LLC boosted its holdings in shares of AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after purchasing an additional 3,064 shares during the last quarter. ProShare Advisors LLC boosted its holdings in shares of AbbVie by 0.8% during the 4th quarter. ProShare Advisors LLC now owns 1,262,493 shares of the company’s stock worth $224,345,000 after purchasing an additional 10,064 shares during the last quarter. Redwood Investment Management LLC boosted its holdings in shares of AbbVie by 599.8% during the 4th quarter. Redwood Investment Management LLC now owns 13,633 shares of the company’s stock worth $2,423,000 after purchasing an additional 11,685 shares during the last quarter. Finally, Raiffeisen Bank International AG acquired a new position in shares of AbbVie during the 4th quarter worth approximately $62,420,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have weighed in on ABBV shares. Guggenheim lifted their price objective on AbbVie from $216.00 to $227.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Bank of America lifted their price objective on AbbVie to $204.00 and gave the company a “hold” rating in a research note on Monday, June 9th. Daiwa America upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 7th. Raymond James Financial reiterated an “outperform” rating on shares of AbbVie in a research note on Monday, August 25th. Finally, Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 22nd. Four investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $222.68.

Insider Activity at AbbVie

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the transaction, the executive vice president directly owned 177,292 shares in the company, valued at $35,178,278.64. The trade was a 19.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Nicholas Donoghoe sold 13,295 shares of the business’s stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total value of $2,639,190.45. Following the transaction, the executive vice president owned 58,247 shares in the company, valued at approximately $11,562,611.97. This represents a 18.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.25% of the company’s stock.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas’ U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman’s academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.